Emerging therapies for the management of hepatic encephalopathy

Seminars in Liver Disease

Volumn 27, Issue SUPPL. 2, 2007, Pages 18-25

  Bass, Nathan M ^a,b,c  

^a Division of Gastroenterology   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Hepatic encephalopathy; Lactulose; Levocarnitine; Rifaximin

Indexed keywords

ACARBOSE; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMMONIA; AMMONUL; ANTIBIOTIC AGENT; BENZOIC ACID; CARNITINE; CREATININE; DISACCHARIDE; LACTITOL; LACTULOSE; NEOMYCIN; PAROMOMYCIN; PHENYLACETATE SODIUM; PHENYLACETIC ACID DERIVATIVE; PROBIOTIC AGENT; RIFAXIMIN; UNCLASSIFIED DRUG;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ALBUMIN DIALYSIS; BLOATING; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DEFECATION DISORDER; DEVICE; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FLATULENCE; GASTROINTESTINAL SYMPTOM; HEPATIC ENCEPHALOPATHY; HOSPITAL PATIENT; HUMAN; LIVER SUPPORT; NAUSEA; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SYSTEMIC THERAPY; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UREA NITROGEN BLOOD LEVEL; VOMITING;

EID: 34548158409     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-984575     Document Type: Review

References (44)

1. Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT. Hepatic encephalopathy-definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology 2002;35:716-721
2. Abou-Assi S, Vlahcevic ZR. Hepatic encephalopathy: metabolic consequence of cirrhosis often is reversible. Postgrad Med 2001;109:52-60, 63
3. Riordan SM, Williams R. Treatment of hepatic encephalopathy. N Engl J Med 1997;337:473-479
4. Blei AT, Cordoba J. Hepatic encephalopathy. Am J Gastroenterol 2001;96:1968-1976
5. Jiang ZD, Ke S, Palazzini E, Riopel L, Dupont H. In vitro activity and fecal concentration of rifaximin after oral administration. Antimicrob Agents Chemother 2000;44:2205-2206
6. Huang DB, DuPont HL. Rifaximin: a novel antimicrobial for enteric infections. J Infect 2005;50:97-106
7. Pakyz AL. Rifaximin: a new treatment for travelers' diarrhea. Ann Pharmacother 2005;39:284-289
8. Paik YH, Lee KS, Han KH, et al. Comparison of rifaximin and lactulose for the treatment of hepatic encephalopathy: a prospective randomized study. Yonsei Med J 2005;46:399-407
9. Mas A, Rodes J, Sunyer L, et al. Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial. J Hepatol 2003;38:51-58
10. Loguercio C, Federico A, De Girolamo V, Ferrieri A, Del Vecchio Blanco C. Cyclic treatment of chronic hepatic encephalopathy with rifaximin: results of a double-blind clinical study. Minerva Gastroenterol Dietol 2003;49:53-62
11. Miglio F, Valpiani D, Rossellini SR, Ferrieri A. Rifaximin, a non-absorbable rifamycin, for the treatment of hepatic encephalopathy: a double-blind, randomised trial. Curr Med Res Opin 1997;13:593-601
12. Williams R, James OF, Warnes TW, Morgan MY. Evaluation of the efficacy and safety of rifaximin in the treatment of hepatic encephalopathy: a double-blind, randomized, dose-finding multi-centre study. Eur J Gastroenterol Hepatol 2000;12:203-208
13. Bucci L, Palmieri GC. Double-blind, double-dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic encephalopathy. Curr Med Res Opin 1993;13:109-118
14. Bass NM. Review article: the current pharmacological therapies for hepatic encephalopathy. Aliment Pharmacol Ther 2007;25(suppl 1):23-31
15. Pedretti G, Calzetti C, Missale G, Fiaccadori F. Rifaximin versus neomycin on hyperammoniemia in chronic portal systemic encephalopathy of cirrhotics: a double-blind, randomized trial. Ital J Gastroenterol 1991;23:175-178
16. Di Piazza S, Gabriella FM, Valenza LM, et al. Rifaximin versus neomycin in the treatment of portosystemic encephalopathy. Ital J Gastroenterol 1991;23:403-407
17. Puxeddu A, Quartini M, Massimetti A, Ferrieri A. Rifaximin in the treatment of chronic hepatic encephalopathy. Curr Med Res Opin 1995;13:274-281
18. Testa R, Eftimiadi C, Sukkar GS, et al. A non-absorbable rifamycin for treatment of hepatic encephalopathy. Drugs Exp Clin Res 1985;11:387-392
19. Bass NM, Ahmed A, Johnson L, et al. Rifaximin treatment is beneficial for mild hepatic encephalopathy. Hepatology 2004;40(suppl 4):646A. Abstract 1116
20. Festi D, Mazzella G, Orsini M, et al. Rifaximin in the treatment of chronic hepatic encephalopathy: results of a multicenter study of efficacy and safety. Curr Ther Res 1993;54:598-609
21. Parini P, Cipolla A, Ronchi M, et al. Effect of rifaximin and paromomycin in the treatment of portal-systemic encephalopathy. Curr Ther Res 1992;52:34-39
22. Sama C, Morselli-Labate AM, Pianta P, et al. Clinical effects of rifaximin in patients with hepatic encephalopathy intolerant or nonresponsive to previous lactulose treatment: an open-label, pilot study. Curr Ther Res 2004;65:413-422
23. Lata J, Hulek P, Spicak J, et al. Safety and efficacy of rifaximin in the treatment of hepatic encephalopathy in liver cirrhosis. Hepatology 2002;36(suppl 2):519A. Abstract 1425
24. Massa P, Vallerino E, Dodero M. Treatment of hepatic encephalopathy with rifaximin: double blind, double dummy study versus lactulose. Eur J Clin Res 1993;4:7-18
25. Giacomo F, Francesco A, Michele N, et al. Rifaximin in the treatment of hepatic encephalopathy. Eur J Clin Res 1993;4:57-66
26. De Marco F, Amato PS, D'Arienzo A. Rifaximin in collateral treatment of portal-systemic encephalopathy: a preliminary report. Curr Ther Res 1984;36:668-674
27. Venturini I, Ferrieri A, Farina F, et al. Evaluation of rifaximin, placebo and lactulose in reducing the levels of benzodiazepine-like compounds in patients with liver cirrhosis: a pilot study. Drugs Exp Clin Res 2005;31:161-168
28. Als-Nielsen B, Gluud LL, Gluud C. Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials. BMJ 2004;328:1046
29. Sigal SH, Stanca CM, Kontorinis N, Bodian C, Ryan E. Diabetes mellitus is associated with hepatic encephalopathy in patients with HCV cirrhosis. Am J Gastroenterol 2006;101:1490-1496
30. Gentile S, Guarino G, Romano M, et al. A randomized controlled trial of acarbose in hepatic encephalopathy. Clin Gastroenterol Hepatol 2005;3:184-191
31. Levocarnitine Injection USP [prescribing information]. Available at: http://www.bedfordlabs.com/products/inserts/levocarnitine_pi.pdf. Accessed March 29, 2007
32. Raskind JY, El Chaar GM. The role of carnitine supplementation during valproic acid therapy. Ann Pharmacother 2000;34:630-638
33. Siciliano M, Annicchiarico BE, Lucchese F, Bombardieri G. Effects of a single, short intravenous dose of acetyl-L-carnitine on pattern-reversal visual-evoked potentials in cirrhotic patients with hepatic encephalopathy. Clin Exp Pharmacol Physiol 2006;33:76-80
34. Malaguarnera M, Pistone G, Elvira R, Leotta C, Scarpello L, Liborio R. Effects of L-carnitine in patients with hepatic encephalopathy. World J Gastroenterol 2005;11:7197-7202
35. Malaguarnera M, Pistone G, Astuto M, et al. Effects of L-acetylcamitine on cirrhotic patients with hepatic coma: randomized double-blind, placebo-controlled trial. Dig Dis Sci 2006;51:2242-2247
36. del Olmo JA, Castillo M, Rodrigo JM, et al. Effect of L-carnitine upon ammonia tolerance test in cirrhotic patients. Adv Exp Med Biol 1990;272:197-208
37. Sushma S, Dasarathy S, Tandon RK, Jain S, Gupta S, Bhist MS. Sodium benzoate in the treatment of acute hepatic encephalopathy: a double-blind randomized trial. Hepatology 1992;16:138-144
38. Efrati C, Masini A, Merli M, Valeriano V, Riggio O. Effect of sodium benzoate on blood ammonia response to oral glutamine challenge in cirrhotic patients: a note of caution. Am J Gastroenterol 2000;95:3574-3578
39. Mendenhall CL, Rouster S, Marshall L, Weesner R. A new therapy for portal systemic encephalopathy. Am J Gastroenterol 1986;81:540-543
40. Liu Q, Duan ZP, Ha DK, Bengmark S, Kurtovic J, Riordan SM. Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology 2004;39:1441-1449
41. Lighthouse J, Naito Y, Helmy A, et al. Endotoxinemia and benzodiazepine-like substances in compensated cirrhotic patients: a randomized study comparing the effect of rifaximine alone and in association with a symbiotic preparation. Hepatol Res 2004;28:155-160
42. Sen S, Mookerjee RP, Davies NA, Williams R, Jalan R. Review article: the molecular adsorbents recirculating system (MARS) in liver failure. Aliment Pharmacol Ther 2002;16(suppl 5):32-38
43. Heemann U, Treichel U, Loock J, et al. Albumin dialysis in cirrhosis with superimposed acute liver injury: a prospective, controlled study. Hepatology 2002;36:949-958
44. Hassanein T, Tpfteng F, Brown R Jr, et al. Efficacy of albumin dialysis (MARS) in patients with cirrhosis and advanced grades of hepatic encephalopathy: a prospective, controlled, randomized multicenter trial [abstract]. Hepatology 2004;4(suppl 1):726A